Merck's Isentress To Treat HIV Treatment Naïve Patients In Japan
This article was originally published in PharmAsia News
Executive Summary
Merck Japanese subsidiary Banyu Pharmaceutical announced a change to insert information for antiretroviral drug Isentress (raltegravir)